JFLLIFE (JFLLIFE) fundamentals
JFLLIFE is a listed company, part of the Pharmaceuticals sector, listed on the NSE as JFLLIFE (ISIN INE0LA901015). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What JFLLIFE does
JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises manufacturing and selling of pharmaceutical products. It is engaged in domestic as well as international business. The Company's main product categories include Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet, and capsules (General) and Oral Rehydration Solutions (ORS). Its beta-lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection, Cefazoline Sodium Injection, meropenem injection, amoxicillin injection, cefTAZidime injection, flucloxacillin injection, among others. Its beta-lactam tablets and capsule products include Cefadroxil Tablets, Cefadroxil Capsules, among others. Its general tablet and capsule products include Azithromycin Tablets, Iburofen Tablets, Ciprofloxacin Tablets, Ofloxacin Tablets, Paracetamol Tablets, among others. These products are offered in different milligrams (mg).
Valuation and market data
| Last close | ₹10.65 |
|---|---|
| Market capitalisation | ₹35 crore |
| Enterprise value | ₹36 crore |
| P/E (TTM) | 0.00 |
| Price to book | 0.89 |
| Price to sales (TTM) | 0.27 |
| Book value per share | ₹11.95 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹131 crore | ₹9 crore | ₹6 crore | 0.00 |
| Mar 2025 | ₹82 crore | ₹6 crore | ₹4 crore | 1.26 |
| Mar 2024 | ₹47 crore | ₹4 crore | ₹3 crore | 1.00 |
| Mar 2023 | ₹44 crore | ₹4 crore | ₹3 crore | 2.90 |
| Mar 2022 | ₹34 crore | ₹4 crore | ₹3 crore | 4.12 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 67.5% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 32.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.